Brain and behavior · 2025
MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer's Disease: Insights from [18F] AV45 and FDG PET Imaging.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saberian Parsa, Darvishi Afra, Khezragha Delnia, Forouzandegan Moojan, Farhadieh Mohammad-Erfan, Taghizadeh Khorshidi Shaghayegh, Hatami Nejad Mohamad, Sedighi Sara, Barati Reza, Safavi Seyed Ahmad Reza, Sadeghi Mohammad, Gulisashvili David, Mayeli Mahsa, Shakeri Shayan
Аннотация
PURPOSE: Alzheimer's disease (AD) is a neurodegenerative disease primarily manifesting with cognitive decline. This study aimed to investigate the alterations in microRNAs in patients across AD continuum as potential biomarkers.
METHOD: Data were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including microRNA levels in the serum and cerebrospinal fluid (CSF) of patients across AD continuum. We analyzed the associations between microRNA levels and previously known AD biomarkers, such as amyloid beta (Aβ) accumulations in the brain and glucose reuptake values using positron emission tomography ([18F]AV45 and FDG PET, respectively).
FINDINGS: The study found a significant positive correlation between CSF levels of miR-210-3p and Aβ accumulations in the brain (B = 4.69). Conversely, miR-223-3p levels were significantly lower in APOE-ε4 carriers. Significant negative correlations were also observed between glucose reuptake and several miRNAs in the AD group. Specifically, plasma levels of let-7g-5p, mir-423-5p, and mir-660-5p were negatively associated with glucose reuptake in the brain.
CONCLUSION: Elevated levels of miR-210-3p correlate with Aβ accumulation, supporting previous findings of increased levels of certain microRNAs in patients with MCI and AD. Our findings highlight the potential of microRNAs as biomarkers of AD.
METHOD: Data were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including microRNA levels in the serum and cerebrospinal fluid (CSF) of patients across AD continuum. We analyzed the associations between microRNA levels and previously known AD biomarkers, such as amyloid beta (Aβ) accumulations in the brain and glucose reuptake values using positron emission tomography ([18F]AV45 and FDG PET, respectively).
FINDINGS: The study found a significant positive correlation between CSF levels of miR-210-3p and Aβ accumulations in the brain (B = 4.69). Conversely, miR-223-3p levels were significantly lower in APOE-ε4 carriers. Significant negative correlations were also observed between glucose reuptake and several miRNAs in the AD group. Specifically, plasma levels of let-7g-5p, mir-423-5p, and mir-660-5p were negatively associated with glucose reuptake in the brain.
CONCLUSION: Elevated levels of miR-210-3p correlate with Aβ accumulation, supporting previous findings of increased levels of certain microRNAs in patients with MCI and AD. Our findings highlight the potential of microRNAs as biomarkers of AD.